Daily Archives: November 26, 2021
2021 DORIS definition of remission in SLE: final recommendations from an international task force.
26 Nov, 2021 | 10:01h | UTC
Systematic Review: Quantifying anticholinergic burden and sedative load in older adults with polypharmacy.
26 Nov, 2021 | 09:58h | UTC
Commentary on Twitter
Systematic review of risk scales for anticholinergic burden and sedative overload – authors developed a comprehensive table on anticholinergics & sedatives (with potency). Check Table 2 and Table S2 (supplementary) for usable info to guide decision-making!https://t.co/JYaSuOeHqv
— Deprescribing (@Deprescribing) November 25, 2021
Guideline on Cutaneous Angiosarcomas – Update 2021.
26 Nov, 2021 | 10:00h | UTCS1-Guideline Cutaneous Angiosarcomas – Update 2021 – Journal of the German Society of Dermatology
Systematic Review: Reducing medication errors for adults in hospital settings.
26 Nov, 2021 | 09:56h | UTCReducing medication errors for adults in hospital settings – Cochrane Library
Commentary on Twitter
Reducing medication errors for adults in hospital.
New review of 65 studies involving over 100,000 participantshttps://t.co/yxGKxumZP0#MedicationErrors #PatientSafety@aciapponi pic.twitter.com/4lb9NNxtpo— Cochrane EPOC (@CochraneEPOC) November 25, 2021
M-A: Treatment for gastrointestinal and pancreatic neuroendocrine tumors.
26 Nov, 2021 | 09:53h | UTCSummary: Treatment options for neuroendocrine tumours – Cochrane Library
Systematic Review: Insufficient evidence to recommend Omega‐3 fatty acids for depression in adults.
26 Nov, 2021 | 09:54h | UTCOmega‐3 fatty acids for depression in adults – Cochrane Library
Commentary on Twitter
'At present, we do not have sufficient high‐certainty evidence to determine the effects of Omega‐3 fatty acids as a treatment for depression in adults' – updated @Cochrane_CCMD systematic review https://t.co/Bg9VNMnyGx
— The Cochrane Library (@CochraneLibrary) November 25, 2021
Opinion: The misuse and abuse of meta-analyses.
26 Nov, 2021 | 09:52h | UTCThe misuse and abuse of meta-analyses – Science-Based Medicine
Phase II RCT: Efficacy and safety of Itepekimab in patients with moderate-to-severe asthma.
26 Nov, 2021 | 09:46h | UTCEfficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries on Twitter
Visual Abstract: Efficacy and Safety of Itepekimab for Moderate-to-Severe Asthma https://t.co/7mldcsSaeW pic.twitter.com/RlvE2Z1Tas
— NEJM (@NEJM) November 3, 2021
In this randomized trial, the monoclonal antibody itepekimab against interleukin-33 improved asthma control in patients with moderate-to-severe asthma. https://t.co/8yNcYumImy pic.twitter.com/YmMP0HjRvA
— NEJM (@NEJM) October 28, 2021
Opinion | Things we do for no reason: prescribing appetite stimulants to hospitalized older adults with unintentional weight loss.
26 Nov, 2021 | 09:44h | UTC
Review: Castleman disease.
26 Nov, 2021 | 09:49h | UTCCastleman disease – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Castleman Disease (if the link is paywalled, try this one)
Visual transformation for guidelines presentation of the strength of recommendations and the certainty of evidence.
26 Nov, 2021 | 09:43h | UTC
Guideline | Endoscopic tissue sampling – Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts.
26 Nov, 2021 | 09:41h | UTC
Closure of Temporary Ileostomy 2 Versus 12 Weeks After Rectal Resection for Cancer: A Word of Caution from a Prospective, Randomized Controlled Multicenter Trial.
26 Nov, 2021 | 09:42h | UTC
Guideline | Endoscopic tissue sampling – Part 2: Lower gastrointestinal tract.
26 Nov, 2021 | 09:39h | UTC
Editorial: Vax the world.
26 Nov, 2021 | 08:40h | UTC
Commentary from the author on Twitter
VAX THE WORLD!
is our wish/plea on #Thanksgiving day
Read our editorial in @ScienceMagazine by @yodifiji and me
Grateful to Lisa Chong, @hholdenthorp & @MeaganPhelan https://t.co/NiwMiEyCld pic.twitter.com/xbj0RF4lQe
— Madhu Pai, MD, PhD (@paimadhu) November 25, 2021
EMA recommends approval of Pfizer-BioNTech vaccine for children aged 5 to 11.
26 Nov, 2021 | 08:47h | UTCRelated:
RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.
What COVID vaccines for young kids could mean for the pandemic.
CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11.
FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.
Commentary on Twitter
‼️ EMA recommends approval of BioNTech/Pfizer’s #COVID19vaccine, Comirnaty, for children aged 5 to 11.
In this population, the dose of #Comirnaty will be lower than that used in people aged 12 and above.
Read the full press release: https://t.co/uqqBAklVvl pic.twitter.com/NZQhli4SDl
— EU Medicines Agency (@EMA_News) November 25, 2021
Heavily mutated coronavirus variant puts scientists on alert – “Researchers are racing to determine whether a fast-spreading variant in South Africa poses a threat to COVID vaccines’ effectiveness”.
26 Nov, 2021 | 08:42h | UTCHeavily mutated coronavirus variant puts scientists on alert – Nature
See also:
Covid: New heavily mutated variant B.1.1.529 in South Africa raises concern – BBC
Scientists warn of new Covid variant with high number of mutations – The Guardian
South Africa detects new COVID variant with many mutations – MedicalXpress
Related commentary on Twitter (thread – click for more)
THREAD on the new variant B.1.1.529 summarising what is known from the excellent South African Ministry of Health meeting earlier today
TLDR: So much uncertain but what *is* known is extremely worrying & (in my opinion) we should revise red list immediately.
This is why: 1/16
— Prof. Christina Pagel (@chrischirp) November 25, 2021
Review: Prevention and management of thrombosis in hospitalized patients with COVID-19 pneumonia.
26 Nov, 2021 | 08:44h | UTC
M-A: Persistent symptoms following SARS-CoV-2 infection among children and young people – “Higher study quality was associated with lower prevalence of all symptoms, except loss of smell and cognitive symptoms”.
26 Nov, 2021 | 08:35h | UTCRelated:
Review: Long COVID symptoms in children rarely persist beyond three months.
Cohort study: Risk factors for long covid in previously hospitalized children.
M-A: More than 50 long-term effects of COVID-19.
M-A: Comparing the clinical efficacy of COVID-19 vaccines.
26 Nov, 2021 | 08:37h | UTC
[Preprint] Serological responses to COVID-19 booster vaccine in England.
26 Nov, 2021 | 08:34h | UTCSerological responses to COVID-19 booster vaccine in England – medRxiv
Commentary from the author on Twitter (thread – click for more)
1/ Our preprint on #SARSCoV2 antibody responses in UK adults receiving a #COVID19 vaccine booster with the Pfizer vaccine at least 6 months after primary immunisation with Pfizer or AZ vaccine, which was given at an extended interval (8-12 wks) … ?
— Shamez Ladhani (@ShamezLadhani) November 25, 2021